Technological advancements of immunoassay products, and their massive adoptions, the surging incidence of chronic and infectious diseases are the major factors driving the growth of the market.
According to the new market research report Immunoassay Market is projected to reach $39.0 billion by 2026, at a CAGR of 6.6% during the forecast period.
Based on technology, the market is segmented into western blotting, radioimmunoassays, ELISA, rapid tests, ELISPOT and other technologies. ELISA accounted for the largest share of the market in 2020. The large share of this segment can be attributed the massive consumption of ELISA in the diagnosis of cancer, infectious diseases, and other chronic complications.
Based on application, the market is segmented into infectious diseases, allergy diagnostics, oncology, endocrinology, cardiology, autoimmune disorders, bone & mineral disorders, toxicology, blood screening, newborn screening and other applications. Infectious diseases account for the largest share of the market, owing to the surging prevalence of infectious diseases and the rising use of immunoassays in diagnostics and management.
The global immunoassay market is consolidated. The prominent players operating in this market include Thermo Fisher Scientific (US), Danaher (US), Abbott Laboratories (US) and Roche (Switzerland).
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436